EXCLUSIVE: Implantable Device Shows Promise In Weight Loss Study
EXCLUSIVE: Implantable Device Shows Promise In Weight Loss Study
At the Benzinga Virtual Healthcare Summit, Adam Mendelsohn, Ph.D., co-founder and CEO of Vivani Medical, discussed the company's innovative approach to chronic disease treatment through miniature implantable devices.
在本辛加虛擬醫療峯會上，Vivani Medical的聯合創始人兼首席執行官亞當·門德爾松博士討論了該公司通過微型植入式設備治療慢性病的創新方法。
These devices are designed to release therapeutic levels of medicine over several months, addressing the widespread issue of medication non-adherence.
這些設備旨在在幾個月內釋放藥物的治療水平，從而解決普遍存在的藥物依從性問題。
New Approach To Medication Delivery
藥物交付的新方法
Vivani Medical's technology aims to improve the translation of clinical results to real-world effectiveness by ensuring consistent medication delivery. "About half of people don't take medicine as prescribed in the real world," Mendelsohn noted, highlighting the gap the company seeks to bridge with its implantable solution.
Vivani Medical的技術旨在通過確保持續的藥物交付，改善臨床結果轉化爲現實世界的有效性。門德爾松指出：“在現實世界中，大約有一半的人不按處方服藥，” 他強調了該公司試圖通過其植入式解決方案彌合的差距。
Breakthrough In Weight Loss Treatment
減肥治療的突破
Mendelsohn also shared recent advancements in the company's preclinical weight loss data for the NPM-115 device. The device showed promising results in obese mice models, with weight loss outcomes comparable to existing therapies.
門德爾松還分享了該公司在 NPM-115 設備臨床前減肥數據方面的最新進展。該設備在肥胖小鼠模型中顯示出令人鼓舞的結果，減肥效果與現有療法相當。
"The weight loss was about 20% from our implant and was also about 20% with the semaglutide injections," Mendelsohn explained, indicating the potential effectiveness of the NPM-115 device in human treatments
門德爾鬆解釋說：“我們的植入使體重減輕了約20％，注射索瑪魯肽的體重也減輕了約20％，” 他指出 NPM-115 設備在人體治療中的潛在有效性
Addressing Medication Adherence Challenges
應對藥物依從性挑戰
The discussion further delved into the challenges of medication adherence, particularly in the context of GLP-1 treatments for weight loss and type 2 diabetes. Mendelsohn emphasized the unique position of Vivani Medical's implantable device in addressing these challenges by providing a steady and controlled release of medication. This approach aims to mitigate common side effects and improve patient compliance.
討論進一步探討了藥物依從性方面的挑戰，特別是在減肥和 2 型糖尿病的 GLP-1 治療背景下。門德爾松強調了Vivani Medical的植入式設備在通過提供穩定和可控的藥物釋放來應對這些挑戰方面的獨特地位。這種方法旨在減輕常見的副作用並提高患者的依從性。
Vivani Medical's development of the NPM-115 device represents a significant step forward in the treatment of chronic diseases. It has the potential to enhance patient outcomes through improved medication adherence and a more convenient treatment regimen. As the company moves towards human testing, the healthcare community watches closely for the impact this technology could have on chronic disease care.
Vivani Medical 開發的 NPM-115 設備代表着在慢性病治療方面向前邁出的重要一步。它有可能通過提高藥物依從性和更便捷的治療方案來改善患者的預後。隨着公司轉向人體試驗，醫療保健界密切關注這項技術可能對慢性病護理產生的影響。
Benzinga Cannabis Capital Conference is coming to Florida
Benzinga 大麻資本會議即將在佛羅里達舉行
The Benzinga Cannabis Capital Conference is returning to Florida in a new venue in Hollywood on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn, and grow.
Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world. Get your tickets now on bzcannabis.com – Prices will increase very soon!
本辛加大麻資本會議將於2024年4月16日和17日在好萊塢的新地點重返佛羅里達州。在外交官海灘度假村舉行的爲期兩天的活動將爲大小企業家提供交流、學習和成長的機會。
這次會議以其引領潮流的能力和對大麻未來的影響而聞名，記住你的日曆——這是大麻界年度必去的活動。立即在bzcannabis.com上購買門票——價格很快就會上漲！
Photo: Shutterstock
照片：Shutterstock
譯文內容由第三人軟體翻譯。